{"id":"continue-ritonavir-boosted-pi-rosuvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Myalgia or muscle pain (statin-related)"},{"rate":null,"effect":"Lipid abnormalities"}]},"_chembl":{"chemblId":"CHEMBL1744447","moleculeType":"Small molecule","molecularWeight":"1001.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ritonavir-boosted protease inhibitors (PIs) block HIV protease, preventing viral maturation and reducing viral load in HIV-infected individuals. Rosuvastatin is a statin that inhibits HMG-CoA reductase to lower LDL cholesterol. This combination addresses both HIV infection and the elevated cardiovascular risk associated with HIV and certain antiretroviral regimens.","oneSentence":"This combination uses ritonavir-boosted protease inhibitor antiretroviral therapy to suppress HIV replication, while rosuvastatin reduces cholesterol levels to manage cardiovascular risk in HIV-positive patients.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:43:43.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced or treatment-naive patients"},{"name":"Hyperlipidemia/cardiovascular risk reduction in HIV-positive patients on protease inhibitor therapy"}]},"trialDetails":[{"nctId":"NCT01935674","phase":"PHASE4","title":"Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2013-09","conditions":"HIV, Hypercholesterolaemia","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Continue Ritonavir-boosted PI+Rosuvastatin","genericName":"Continue Ritonavir-boosted PI+Rosuvastatin","companyName":"Juan A. Arnaiz","companyId":"juan-a-arnaiz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses ritonavir-boosted protease inhibitor antiretroviral therapy to suppress HIV replication, while rosuvastatin reduces cholesterol levels to manage cardiovascular risk in HIV-positive patients. Used for HIV-1 infection in treatment-experienced or treatment-naive patients, Hyperlipidemia/cardiovascular risk reduction in HIV-positive patients on protease inhibitor therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}